History Mission Strategic plan Role The FAMHP also ensures that … Our core business Our organisation Organisation chart Our vision and values Vision and ambition Values Commitments by federal administrations Our stakeholders Partners FAMHP customer charter Partners receiving financial support from the FAMHP The FAMHP and European projects Disclaimer Transparency Social media Conditions for reuse (Creative Commons-0 licence)
04/09/2024 Limited availability of medicinal product based on peginterferon alfa-2a, solution for injection: recommendations for physicians (-specialists) and (hospital) pharmacists.
20/08/2024 Call to professionals responsible for materiovigilance: take part in European Commission survey on electronic instructions for use
06/08/2024 Warning: serious adverse reactions when administering the veterinary medicinal product Senvelgo (velagliflozin molecule) to cats suffering from diabetes